• 1. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

Chemical Profile of 4-Ethyl-1-methyl-4-piperidinol (CAS No. 20734-31-0)

4-Ethyl-1-methyl-4-piperidinol, identified by its Chemical Abstracts Service (CAS) number 20734-31-0, is a compound of significant interest in the field of pharmaceutical chemistry and medicinal biology. This piperidine derivative exhibits a unique structural framework that has garnered attention for its potential applications in drug discovery and development. The presence of both ethyl and methyl substituents on the piperidine ring, along with a hydroxyl group at the fourth position, contributes to its distinct chemical properties and reactivity, making it a valuable candidate for further investigation.

The compound’s molecular structure, characterized by a six-membered heterocyclic ring containing nitrogen, is a hallmark of many bioactive molecules. Piperidine derivatives are widely recognized for their role in the synthesis of various pharmacologically active agents, including antipsychotics, antihistamines, and cardiovascular drugs. The specific arrangement of functional groups in 4-Ethyl-1-methyl-4-piperidinol may influence its pharmacokinetic behavior, binding affinity to biological targets, and overall therapeutic efficacy.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the interactions of 4-Ethyl-1-methyl-4-piperidinol with biological macromolecules. These studies suggest that the compound may exhibit inhibitory activity against certain enzymes and receptors implicated in neurological disorders. For instance, preliminary virtual screening experiments have indicated potential binding to serotonin receptors, which are key targets in the treatment of depression and anxiety disorders. Such findings align with the growing interest in developing novel psychoactive agents with improved selectivity and reduced side effects.

In the realm of medicinal chemistry, the synthesis of 4-Ethyl-1-methyl-4-piperidinol has been optimized to enhance yield and purity. Modern synthetic methodologies, including catalytic hydrogenation and nucleophilic substitution reactions, have been employed to construct the piperidine core efficiently. The hydroxyl group at the fourth position provides a versatile handle for further derivatization, allowing chemists to explore analogs with tailored pharmacological properties. This flexibility is particularly valuable in drug development pipelines where structural modifications can fine-tune biological activity.

The compound’s physicochemical properties, such as solubility and stability, are critical factors in determining its suitability for pharmaceutical applications. Experimental data indicate that 4-Ethyl-1-methyl-4-piperidinol exhibits moderate solubility in both water and organic solvents, which could facilitate its formulation into diverse dosage forms. Additionally, its stability under various storage conditions makes it a promising candidate for industrial-scale production. These attributes are essential for ensuring the compound’s viability in clinical trials and eventual commercialization.

Current research endeavors are focused on elucidating the mechanism of action of 4-Ethyl-1-methyl-4-piperidinol by integrating experimental data with computational approaches. Preclinical studies have begun to explore its effects on model systems relevant to neurological disorders. For example, animal models have been used to assess its potential as an anxiolytic or antidepressant agent. While these studies are still in early stages, they provide encouraging evidence of the compound’s therapeutic promise.

The development of novel drug candidates often involves interdisciplinary collaboration between chemists, biologists, and clinicians. 4-Ethyl-1-methyl-4-piperidinol serves as an excellent example of how structural diversity can lead to innovative therapeutic solutions. By leveraging cutting-edge synthetic techniques and biophysical methods, researchers aim to uncover new applications for this compound in areas such as pain management and neuroprotection.

The regulatory landscape for pharmaceutical compounds necessitates rigorous testing to ensure safety and efficacy before human use. As such, 4-Ethyl-1-methyl-4-piperidinol is being evaluated through comprehensive toxicological assessments to determine its potential adverse effects. These studies are designed to provide regulators with the necessary data to support future clinical investigations if warranted.

Future directions in the study of 4-Ethyl-1-methyl-4-piperidinol may include exploring its role as a scaffold for next-generation therapeutics. By modifying its core structure or appending additional functional groups, chemists can generate libraries of derivatives with enhanced pharmacological profiles. Such efforts could lead to breakthroughs in treating complex diseases where existing treatments are limited or ineffective.

In conclusion, 4-Ethyl-1-methyl-4-piperidinol (CAS No. 20734-31-0) represents a compelling subject of study within pharmaceutical chemistry. Its unique structural features offer opportunities for innovation across multiple therapeutic domains. As research progresses，this compound is poised to contribute significantly to advancements in drug discovery，with potential implications for improving human health worldwide.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)